EBMT 2019 | MRD negativity in ALL
Dieter Hoelzer
Dieter Hoelzer, MD, PhD, from the University of Frankfurt, Frankfurt, Germany, explores the importance of MRD negativity in acute lymphoblastic leukemia (ALL). Dr Hoelzer was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Related videos
5:23 Treatment options for Ph+ ALL
Oliver Ottmann
5:01 Challenges of CAR T-cell treatment in pediatric ALL
Christina Peters
3:07 How age as a prognostic factor affects treatment options for ALL
Oliver Ottmann
4:15 Impacts and effects of CAR T-cell therapy for pediatric ALL
Christina Peters
3:24 Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann
